Search results
Showing 106 to 120 of 1243 results for public health guidance
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]
In development Reference number: GID-TA11116 Expected publication date: 11 November 2026
In development Reference number: GID-TA11776 Expected publication date: TBC
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]
Awaiting development Reference number: GID-TA11215 Expected publication date: 14 July 2026
Awaiting development Reference number: GID-TA11978 Expected publication date: TBC
In development Reference number: GID-TA11340 Expected publication date: TBC
This quality standard covers assessing, diagnosing and managing physical health problems of adults aged 18 years and older in prisons or young offender institutes. It describes high-quality care in priority areas for improvement.
View quality statements for QS156Show all sections
Sections for QS156
- Quality statements
- Quality statement 1: Medicines reconciliation
- Quality statement 2: Second-stage health assessment
- Quality statement 3: Blood-borne viruses and sexually transmitted infections
- Quality statement 4: Lead care coordinator
- Quality statement 5: Medicines on transfer or discharge
- Update information
- About this quality standard
In development Reference number: GID-TA11356 Expected publication date: TBC
This guideline covers interventions to prevent sexually transmitted infections (STIs) in people aged 16 and over. It aims to reduce the transmission of all STIs, including HIV, and includes ways to help increase the uptake of STI testing and vaccines for human papillomavirus (HPV) and hepatitis A and B.
This guideline aims to increase the uptake of all vaccines provided on the NHS routine UK immunisation schedule by everyone who is eligible. It supports the aims of the NHS Long Term Plan , which includes actions to improve immunisation coverage by GPs (including the changes to vaccinations and immunisations detailed in the 2021/2022 and 2022/23 GP contracts ) and support a narrowing of health inequalities.
Norucholic acid for treating primary sclerosing cholangitis [ID6583]
Awaiting development Reference number: GID-TA11782 Expected publication date: 29 April 2027
Bepirovirsen with nucleoside or nucleotide analogues for treating chronic hepatitis B [ID6608]
In development Reference number: GID-TA11803 Expected publication date: 10 March 2027
Brentuximab vedotin in combination for untreated advanced classical Hodgkin lymphoma [ID6437]
In development Reference number: GID-TA11516 Expected publication date: 06 May 2027
Awaiting development Reference number: GID-TA11907 Expected publication date: 10 June 2027
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]
In development Reference number: GID-TA11454 Expected publication date: 23 July 2026
In development Reference number: GID-TA11052 Expected publication date: 17 February 2027